PO.ET04.01 · 实验与分子治疗

用于定量体内CAR-T递送系统的生物发光工具

Bioluminescent tools for quantification of in vivo CAR‑T delivery systems

海报缩略图:用于定量体内CAR-T递送系统的生物发光工具
编号 275 展板 18 时间 4/19 02:00–05:00 区域 Section 12 主讲 Steven Edenson, BS;MBA
分会场 Gene and Vector-Based Therapy
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Julia K. Gilden1, Pete Stecha2, Rich Moravec2, Jun Wang3, Rod Flemming1, Jim Harnett1, Steven Edenson1, Kristin Riching1, Jamison Grailer1, Mei Cong2

1Promega, Madison, WI,2R&D, Promega, Madison, WI,3Promega, Fitchburg, WI

摘要 Abstract

中文摘要
使用mRNA-LNP、慢病毒(LV)或AAV载体进行体内CAR-T工程改造,需要在CMC和生物测定工作流程中快速、可扩展且具有机制信息量的分析方法。我们组建了一套集成的发光工具包,用于定量载体投入量、功能效价和固有免疫风险。对于mRNA-LNP,Lumit® dsRNA检测测定采用分裂荧光素酶系统,定量可触发固有感应并降低转染效率的双链RNA杂质。为更广泛评估免疫原性,基于细胞的TLR报告基因测定可分析载体或制剂诱导的通路激活。为定量LV载体,均相、免洗的Lumit® p24免疫测定在约60分钟内测量LV p24衣壳蛋白,作为病毒颗粒计数的替代指标,具有宽线性范围。功能效价可使用基于细胞的报告基因生物测定来测量,其中稳定表达NFAT-Luc2报告基因的Jurkat T细胞被CAR LV转导,并与抗原阳性靶细胞共培养,产生反映LV身份和效价的抗原依赖性发光信号。这些测定共同简化了体内CAR-T递送系统的开发、放行和可比性评估。
查看英文原文 English abstract
In vivo CAR‑T engineering using mRNA-LNP, lentiviral (LV), or AAV vectors requires analytical methods that are rapid, scalable, and mechanistically informative across CMC and bioassay workflows. We assembled an integrated luminescent toolkit to quantify vector input, functional potency, and innate‑immune risk. For mRNA-LNP, a Lumit® dsRNA detection assay uses a split luciferase system to quantify double‑stranded RNA impurities that can trigger innate sensing and diminish transfection. For broader assessment of immunogenicity, cell‑based TLR reporter assays profile vector‑ or formulation‑induced pathway activation. For quantification of LV vectors, the homogeneous, no‑wash Lumit® p24 Immunoassay measures the LV p24 capsid protein as a surrogate for viral particle count with a wide linear range in ~60 minutes. Functional potency can be measured using a cell-based reporter bioassay in which Jurkat T cells stably expressing an NFAT-Luc2 reporter are transduced with CAR LV and co‑cultured with antigen‑positive targets to generate an antigen‑dependent luminescent signal that reflects LV identity and potency. Together, these assays streamline development, release, and comparability for in vivo CAR‑T delivery systems.
利益披露 Disclosure
J. K. Gilden, None.. P. Stecha, None.. R. Moravec, None.. J. Wang, None.. R. Flemming, None.. J. Harnett, None.. S. Edenson, None.. K. Riching, None.. J. Grailer, None.. M. Cong, None.

← 返回 AACR 2026 检索